triqk Antibody

What are the different phases of antibody clinical trials and their key objectives?

Antibody clinical trials typically progress through distinct phases with specific objectives:

• Phase 1 trials: Focus on safety, tolerability, and pharmacology in healthy subjects or patients. These trials establish maximum tolerable dose (MTD) and evaluate preliminary pharmacokinetics.

  For example, in the phase 1 trial of mRNA-1944 (an antibody against Chikungunya virus), the primary outcome was "to evaluate the safety and tolerability of escalating doses of mRNA-1944 administered via intravenous infusion in healthy participants aged 18–50 years." Secondary objectives included determining pharmacokinetics and pharmacodynamics .

• Phase 1b trials: Often examine specific patient populations or combination therapies.

  As seen in the Rockefeller University HIV antibody trial, 18 participants received seven infusions of broadly neutralizing antibodies while discontinuing antiretroviral medications to assess viral suppression capabilities .

• Phase 2 trials: Evaluate efficacy against placebo or standard of care while continuing to monitor safety.

• Phase 3 trials: Large-scale confirmation of efficacy and safety across broader populations.

How do researchers determine appropriate dosing for first-in-human antibody trials?

Determining the initial dosing for first-in-human (FIH) antibody trials involves several methodological approaches:

• Target-mediated drug disposition (TMDD) modeling: This approach integrates binding affinity constants and internalization rates to predict human dosing from animal studies.

• Minimal anticipated biological effect level (MABEL): This conservative approach selects starting doses that produce minimal target coverage.

For example, in a study of TAM-163 (an agonist antibody targeting TrkB receptors), researchers used TMDD modeling based on monkey studies to determine that:

• A subcutaneous dose of 0.05 mg/kg was recommended as the starting dose for FIH trials

• This dose was projected to achieve <10% target coverage at maximum concentration

• Doses of 1 and 15 mg/kg were projected to be minimally and fully pharmacologically active, respectively .

What methods are used to evaluate antibody pharmacokinetics in clinical trials?

Researchers employ several approaches to assess antibody pharmacokinetics:

• Sampling timeline: Blood samples are typically collected at predetermined intervals:

  • Pre-dose

  • Mid-infusion (e.g., 0.5-1.5 hours)

  • End of infusion (e.g., 1-3 hours plus 5 minutes)

  • Multiple timepoints post-infusion (2, 4, 6, 8, 12, 18, 24, 36, 48 hours)

  • Extended timepoints (days 7, 14, 21, 28 and potentially weeks 8, 12, 24, 36, 48, 52)

• Key parameters measured:

  • Area under the concentration-time curve (AUC)

  • Maximum observed serum concentration (Cmax)

  • Time to maximum concentration (Tmax)

  • Half-life (t1/2)

  • Clearance and volume of distribution

• Special considerations for antibody-drug conjugates (ADCs):

  • Drug-antibody ratio (DAR) distribution

  • Free versus conjugated antibody concentrations

  • Release kinetics of the payload

How do antibody half-lives vary across different therapeutic classes?

Antibody half-lives show significant variation across therapeutic classes, influencing dosing schedules and clinical applications:

Data compiled from multiple clinical studies

What are bispecific antibodies and how do their clinical trial designs differ from conventional monoclonal antibodies?

Bispecific antibodies simultaneously target two different epitopes or antigens, creating unique considerations for clinical trial design:

• Mechanism of action: Unlike conventional antibodies, bispecifics can:

  • Redirect immune cells to tumor cells (e.g., CD3 × tumor antigen)

  • Simultaneously block two pathways (e.g., PD-L1 × 4-1BB)

  • Create tri-cell complexes between tumor cells, T cells, and accessory cells

• Dosing considerations: Bispecifics often require different dosing strategies:

  • Lower starting doses due to increased risk of cytokine release

  • More gradual dose escalation protocols

  • Monitoring of unique immunological parameters

For example, the bispecific antibody DuoBody-PD-L1×4-1BB (GEN1046) combines PD-L1 blockade with conditional 4-1BB stimulation, demonstrating "pharmacodynamic immune effects in peripheral blood consistent with its mechanism of action, manageable safety, and early clinical activity [disease control rate: 65.6% (40/61)]" in patients with advanced refractory solid tumors .

How are site-specific conjugation methods improving the homogeneity of antibody-drug conjugates?

Site-specific conjugation represents a significant advancement over conventional stochastic methods:

• Conventional approaches and limitations:

  • Lysine conjugation: While commonly used (as in gemtuzumab ozogamicin, T-DM1), an antibody contains approximately 80-90 lysine residues, resulting in heterogeneous products with varying drug-antibody ratios (DARs) .

  • Random cysteine conjugation: Creates inconsistent conjugation sites and heterogeneous products.

• Site-specific conjugation technologies:

  • ThioMab technology: Introduces engineered cysteine residues at specific positions (e.g., light chain V110A and heavy chain A114C), resulting in "as high as 92.1%" of the product having the target DAR of 2 .

  • Disulfide re-bridging: Employs cysteine-selective cross-linking reagents such as bissulfone reagents, next-generation maleimides, and pyridazinediones to reconnect polypeptide chains while simultaneously attaching payloads .

These technologies have enabled third-generation ADCs with "lower toxicity and higher anticancer activity, as well as higher stability, allowing patients to receive better anticancer therapeutics" .

What strategies can prevent or mitigate cytokine release syndrome in antibody clinical trials?

Cytokine release syndrome (CRS) represents a significant safety concern in antibody trials, as highlighted by the TGN1412 incident where all six healthy volunteers experienced life-threatening "cytokine storms" . Prevention and mitigation strategies include:

• Improved preclinical testing:

  • Development of "novel in vitro procedures in which [antibodies are] immobilized in various ways... to predict the toxicity of superagonists"

  • Consideration of species differences in receptor expression and antibody binding

• Clinical trial design modifications:

  • Starting with ultra-low doses based on the Minimal Anticipated Biological Effect Level (MABEL)

  • Sequential dosing of participants with adequate observation periods

  • Pre-medication with corticosteroids for higher-risk antibodies

• Biomarker monitoring:

  • Real-time monitoring of cytokines (IL-6, TNF-α, IFN-γ, IL-2)

  • C-reactive protein and complement activation

  • Changes in lymphocyte counts and activation markers

For example, in the mRNA-1944 trial, researchers monitored "C-reactive protein, complement, interleukin-6 (IL-6) and interferon gamma-induced protein 10 (IP-10)" and observed "transient increases... at 12–24 h postdose that rapidly declined during 48 h" .

How are immunogenicity risks assessed and managed in therapeutic antibody development?

Immunogenicity assessment follows a structured approach:

• Risk factors evaluation:

  • Antibody humanization level (chimeric, humanized, fully human)

  • Presence of aggregates or particulates

  • Posttranslational modifications and degradation products

  • Route of administration and dosing frequency

• Preclinical immunogenicity assessment:

  • In silico T-cell epitope prediction

  • HLA binding assays

  • T-cell assays with human blood cells

• Clinical immunogenicity monitoring:

  • Anti-drug antibody (ADA) assays at multiple timepoints

  • Neutralizing antibody assays

  • Impact assessment on pharmacokinetics, efficacy, and safety

• Immunogenicity management strategies:

  • Removal of high-risk motifs through protein engineering

  • Formulation optimization to reduce aggregation

  • Concomitant immunosuppression in certain cases

For example, in the L9LS malaria antibody trial, researchers monitored for the development of anti-PEG antibodies and anti-drug antibodies, noting that "None of the participants treated with mRNA-1944 had detectable anti-PEG or anti-CHKV-24 IgG antibodies before or after administration of treatment at all doses" .

What developability assessments should be performed during early-stage antibody discovery?

Early-stage developability assessment is critical for identifying and mitigating risks before significant resources are invested:

• Critical physicochemical properties:

  • Thermal stability (Tm, Tagg)

  • Colloidal stability (kD, zeta potential)

  • Solubility at high concentrations

  • Isoelectric point

• Sequence-based risk assessment:

  • Posttranslational modification hotspots (deamidation, oxidation, glycosylation)

  • Unusual residues or sequence variations

  • Proteolytic cleavage sites

  • High-risk motifs (NG/NS/DG motifs, unpaired cysteines)

• Experimental methods:

  • Differential scanning calorimetry (DSC)

  • Size exclusion chromatography (SEC)

  • Analytical ultracentrifugation

  • Light scattering techniques

  • Accelerated stability studies

"When sequences of the antibodies are available, in silico analysis should be performed to mark PTM hotspots, unusual residues at particular positions, deletion or addition of sequences, etc." . High-risk motifs "should be removed to mitigate potential risks to efficacy and safety" .

How do researchers optimize antibody candidates identified with developability issues?

When developability issues are identified, several optimization approaches can be employed:

• Structure-guided engineering:

  • Targeted mutagenesis of problematic residues

  • CDR grafting or back-mutations

  • Framework optimization

• High-throughput optimization campaigns:

  • Phage display library screening with developability filters

  • Combinatorial mutagenesis of multiple positions

  • Machine learning-guided optimization

• Case studies of successful optimization:

  • "Deletion of two hydrophobic residues in the CDR domains of a mAb significantly reduced its tendency to precipitation"

  • "Removal of deamidation site in the CDR H2 of anti-GUCY2C and of proteolytic cleavage site in the CDR H2 of anti-CD3 reduced its polyreactivity and self-association potential"

The goal is to create "a well-behaved [antibody] suitable for manufacturing... After multidimensional optimization campaigns" .

How are antibody therapies being applied beyond oncology and infectious diseases?

While antibody therapies have traditionally focused on cancer and infectious diseases, emerging applications include:

• Autoimmune and inflammatory conditions:

  • Glucocorticoid-based antibody-drug conjugates for rheumatoid arthritis

  • ABBV-3373, "a proprietary dexamethasone derivative on the anti-TNF-α adalimumab," was developed "against autoimmune disease and specifically rheumatoid arthritis"

  • These conjugates allow targeted delivery of anti-inflammatory agents to affected tissues while "minimizing systemic adverse effects associated with standard glucocorticoid treatment"

• Neurological disorders:

  • Antibodies against enterovirus D68 for acute flaccid myelitis

  • The experimental antibody EV68-228-N is being tested against enterovirus D68, which can cause "severe respiratory disease and — in rare cases — a debilitating, polio-like neurologic condition" called acute flaccid myelitis

• Personalized approaches:

  • Patient-derived antibodies for targeted therapies

  • The EV68-228-N antibody "was isolated at VUMC from people who had EV-D68 respiratory infections" , exemplifying how patient-oriented research can lead to therapeutic antibody development

What are the latest advances in antibody delivery technologies?

Novel delivery technologies are expanding the utility and accessibility of antibody therapies:

• mRNA-encoded antibodies:

  • Instead of directly administering antibody proteins, lipid nanoparticle-encapsulated mRNA encoding antibodies can be delivered

  • For example, mRNA-1944 encodes "the heavy and light chains of a CHIKV-specific monoclonal neutralizing antibody, CHKV-24"

  • This approach resulted in "dose-dependent neutralizing antibody titers... in all participants" with "PRNT50 GMTs >100, a level previously associated with protection from CHIKV infection in humans"

• Subcutaneous versus intravenous administration:

  • Development of more concentrated, stable formulations enables subcutaneous administration

  • The malaria antibody L9LS is "a different, injectable antibody" that replaced CIS43LS which was "cumbersome to deliver, having to be infused directly into a person's bloodstream over about half an hour"

  • This advancement allows for more practical field deployment in resource-limited settings

• Extended half-life technologies:

  • Fc engineering for enhanced FcRn binding

  • PEGylation and other conjugation approaches

  • Novel formulations for sustained release

These advances are particularly impactful for global health applications, as seen in the malaria antibody trials where "a long-acting monoclonal antibody delivered at a single health care visit that rapidly provides high-level protection against malaria in these vulnerable populations would fulfill an unmet public health need" .

How are efficacy endpoints selected and analyzed in antibody clinical trials?

Efficacy endpoint selection varies by disease area and mechanism of action:

What specialized analytical techniques are required for antibody-related biomarker assessment?

Antibody trials require sophisticated analytical approaches:

• Immunogenicity assessment:

  • Multi-tiered approach (screening, confirmation, characterization)

  • Assessment of binding vs. neutralizing antibodies

  • Specialized assays to overcome drug interference

• Target engagement assessment:

  • Flow cytometry for receptor occupancy

  • Proximal PD biomarkers

  • Competitive binding assays

• Functional biomarkers:

  • Cytokine multiplex panels

  • Immune cell phenotyping

  • Gene expression profiling

  • For example, in the trial of anti-PD-L1 antibody LY3300054, "High-content molecular analysis of tumor and peripheral tissues from animals treated with LY3300054 reveals distinct adaptive immune activation signatures, and also previously not described modulation of innate immune pathways"

• Novel technologies:

  • Mass cytometry (CyTOF)

  • Single-cell RNA sequencing

  • Spatial transcriptomics

  • Digital pathology with multiplex immunofluorescence